Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.

Alimentary pharmacology & therapeutics - 1 Jul 2017

Ananthakrishnan A N, Sakuraba A, Barnes E L, Pekow J, Raffals L, Long M D, Sandler R S

Abstract excerpt

BACKGROUND: The impact of combination therapy on disease-related morbidity in patients with established Crohn's disease (CD) or ulcerative colitis (UC) remains to be well-defined. AIM: To examine the effect of combination therapy on disease outcomes in CD and UC. METHODS: Using a multicenter prospective cohort, we classified CD and UC patients as being on monotherapy with anti-TNF or on combination with an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Products
Share to Colitis, Ulcerative

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crohn Disease

Share to Drug Therapy, Combination

Share to Gastrointestinal Agents

Share to Inflammatory Bowel Diseases

Share to Infliximab

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 28470787
DOI: 10.1111/apt.14125
PMCID: PMC5484085

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.PMID 28470787Read ↗

Impact of medical therapy on patients with Crohn's disease requiring surgical resection.Semantic proximity Read ↗

Crohn's disease.Semantic proximity Read ↗

The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases.Semantic proximity Read ↗

Comparative Effectiveness and Safety of Ustekinumab versus Anti–TNF Therapy in Crohn Disease: A Systematic ReviewSemantic proximity Read ↗

5-aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study.Semantic proximity Read ↗

The changing face of Crohn's disease: a population-based study of the natural history of Crohn's disease in Örebro, Sweden 1963-2005.Semantic proximity Read ↗

Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.Semantic proximity Read ↗

A Comparative Analysis of Drug Therapy, Disease Phenotype, and Health Care Outcomes for Men and Women with Inflammatory Bowel Disease.Semantic proximity Read ↗

Meta-analysis of early bowel resection versus initial medical therapy in patient's with ileocolonic Crohn's disease.Semantic proximity Read ↗

Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis.Semantic proximity Read ↗

Determinants of fatigue in Crohn's disease patients.Semantic proximity Read ↗

Recent advances: Personalised use of current Crohn's disease therapeutic options.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.